Black Rock Inc. Aldeyra Therapeutics, Inc. Call Options Transaction History
Black Rock Inc.
- $4.35 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALDX
# of Institutions
139Shares Held
38.6MCall Options Held
620KPut Options Held
435K-
Perceptive Advisors LLC New York, NY9.28MShares$19.9 Million2.23% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$11.8 Million21.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.72MShares$7.99 Million0.0% of portfolio
-
Ardsley Advisory Partners LP Stamford, CT1.75MShares$3.76 Million2.26% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.23MShares$2.65 Million0.18% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $125M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...